Breath Therapeutics, a Zambon company, initiates BOSTON-3 and BOSTON-4, two additional clinical studies for the treatment of bronchiolitis obliterans syndrome (BOS)

February 20, 2020 – Zambon, a multinational pharmaceutical company that focuses on innovation and development with the aim to improve the quality of people’s health and patients’ lives, and Breath Therapeutics, a Zambon company, specializing in advanced inhaled therapeutics for severe respiratory diseases, announced today the initiation of the BOSTON-4 phase 2 multi-center clinical study of Liposomal Cyclosporine A for Inhalation (LCsAi) for the treatment of bronchiolitis obliterans syndrome (BOS) following allogeneic hematopoietic stem cell transplant (alloHSCT). Additionally, the BOSTON-3 open-label extension study has been initiated and is open to eligible participants who complete the BOSTON1 and 2 phase 3 studies currently underway to evaluate LCsAi for the treatment of BOS following lung transplantation.